Peresolimab

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

ArthritisAutoimmune DiseasesConnective Tissue DiseasesHealthyImmune System DiseasesJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Phase 1

A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy Participants

CompletedNCT05959109

Eli Lilly and CompanyHealthy

Start: 2023-07-21End: 2024-01-11Updated: 2024-01-29

Phase 2

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

TerminatedNCT05516758

Eli Lilly and CompanyArthritis, Autoimmune Diseases, Connective Tissue Diseases +5

Start: 2022-08-31End: 2025-01-17Updated: 2025-12-04